Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPAC and systemic chemotherapy in malignant peritoneal mesothelioma
NCT03875144Phase 2Suspended
- Sponsor
- Institut du Cancer de Montpellier
- Start
- Sep 2020
- Primary completion
- Dec 2024
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pegylated liposomal doxorubicin in peritoneal mesothelioma, sponsored by Institut du Cancer de Montpellier. Primary endpoint: Overall Survival. Started Sep 2020; status: suspended.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
peritoneal mesothelioma
Beyond the preview
Go deeper on NCT03875144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03875144.